- Ticker
- ACE.ST
- Price
- 9.44
- Stock movement up
- +0.39 (4.31%)
- Company name
- Ascelia Pharma AB (publ)
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 318.34M
- Ent value
- 162.33M
- Price/Sales
- -
- Price/Book
- 1.38
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -35.34%
- 3 year return
- -38.18%
- 5 year return
- -17.83%
- 10 year return
- -
Last updated: 2024-04-09
DIVIDENDS
ACE.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.38 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 33.72M |
| EPS (TTM) | -3.35 |
| FCF per share (TTM) | -3.83 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -134.00M |
| Net income (TTM) | -112.91M |
| EPS (TTM) | -3.35 |
| EPS (1y forward) | -7.20 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 179.81M |
| Net receivables | 8.80M |
| Total current assets | 196.15M |
| Goodwill | 0.00 |
| Intangible assets | 57.07M |
| Property, plant and equipment | 0.00 |
| Total assets | 254.09M |
| Accounts payable | 3.86M |
| Short/Current long term debt | 723.00K |
| Total current liabilities | 23.56M |
| Total liabilities | 23.80M |
| Shareholder's equity | 230.29M |
| Net tangible assets | 173.22M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -128.79M |
| Capital expenditures (TTM) | 167.00K |
| Free cash flow (TTM) | -128.96M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -49.03% |
| Return on Assets | -44.44% |
| Return on Invested Capital | -48.93% |
| Cash Return on Invested Capital | -55.88% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 9.06 |
| Daily high | 9.66 |
| Daily low | 9.06 |
| Daily Volume | 123K |
| All-time high | 63.10 |
| 1y analyst estimate | 65.00 |
| Beta | 0.86 |
| EPS (TTM) | -3.35 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 16 May 2024 |
Downside potential
Loading...
Downside potential data
| ACE.ST | S&P500 | |
| Current price drop from All-time high | -85.04% | -0.85% |
| Highest price drop | -95.74% | -56.47% |
| Date of highest drop | 30 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -50.77% | -11.35% |
| Avg time to new high | 71 days | 13 days |
| Max time to new high | 837 days | 1805 days |
COMPANY DETAILS
Marketcap
318.34M
Marketcap category
Small-cap
Description
Ascelia Pharma AB (publ), a biotech company, engages in the development of oncology-focused orphan drugs in Sweden. The company offers Orviglance (Mangoral), a novel non-gadolinium contrast agent, which is in Phase 3 development for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found